WeVote
Log In

Bill

Bill

S 724

Relates to ADA or handicapped parking spaces at an arena

2025 Regular Session Introduced by Steve Rhoads

Reforms PBMs and insurers to pass through at least 80% of estimated rebates to patients at point of sale, cutting out-of-pocket costs and mandating annual compliance reporting.

REFERRED TO TRANSPORTATION
0
WeVote Research Nonpartisan
Bill Summary · S 724

Summary — S 724 (2025): "An Act promoting healthcare access and affordability for patients"

Overview

S 724 is a Massachusetts Senate bill (filed Jan 16, 2025; introduced Feb 25, 2025) that would (1) repeal two sections of a 2012 act, (2) add a new consumer-protection section to chapter 176O of the General Laws governing carriers and pharmacy benefit managers (PBMs), and (3) require a Health Policy Commission (HPC) / Executive Office of Health and Human Services (EOHHS) analysis and report on the anticipated rollout and access implications of cell and gene therapies (forecast period 2027–2037). The bill’s stated purpose is to promote healthcare access and affordability.

Note: some submitted metadata (title referencing ADA/handicapped parking at an arena and sponsor names) appears inconsistent with the bill text; this summary is based on the bill text provided.

Key provisions

1) Repeal

  • Repeals Sections 131 and 226 of Chapter 139 of the Acts of 2012 (text of those sections is not included in the provided material).

2) Rebates and point-of-sale cost-sharing reductions (new Section 31 to Chapter 176O)

  • Definitions: establishes terms including “cost-sharing,” “estimated rebate,” “pharmacy benefit manager,” and “price protection rebate.”
  • Point-of-sale pass-through: requires a carrier or any PBM to make available to an insured at least 80% of estimated rebates by reducing the insured’s defined cost-sharing at the point of sale. Reductions cannot create a net credit at point-of-sale.
  • Good-faith estimates: neither insured nor carrier is responsible for any difference between estimated and actual rebate amounts provided the estimates were made in good faith.
  • PBM flexibility: PBMs may reduce cost-sharing by more than 80% if they choose.
  • Confidentiality: actual rebate amounts by product, therapeutic class, manufacturer or pharmacy are treated as trade secrets/confidential commercial information and are exempt from public records disclosure. PBMs must extend confidentiality protections to agents/third-party administrators.
  • Regulatory limits: the Division may regulate carriers/PBMs only to the extent permissible under applicable law.
  • Reporting & enforcement: carriers must file an annual compliance report with the Division by April 1. The commissioner may order compliance and impose fines up to $5,000 per day for continued noncompliance.

3) Cell and gene therapy analysis & report

  • Mandates HPC together with EOHHS to analyze and report on the “future of cell and gene therapy” with an emphasis on access for MassHealth beneficiaries and other vulnerable populations.
  • Required elements include:
    • Projected number and therapeutic indications of products expected in U.S. market during 2027–2037, including estimated lives impacted and number receiving care under MassHealth.
    • Assessment of current MassHealth reimbursement frameworks for therapies administered in inpatient settings.
    • Evaluation of whether reimbursement approaches will create barriers to access and whether impacts will disproportionately affect MassHealth or vulnerable groups (including racial/ethnic minorities).
    • Assessment of facility/infrastructure readiness for administration of such therapies and equitable access (text truncated in provided copy — bill likely lists additional required analyses).

Who would be affected

  • Insured patients (commercially insured and possibly MassHealth beneficiaries) — likely lower out-of-pocket cost at point-of-sale for prescription drugs due to rebate pass-through.
  • Insurance carriers and PBMs — operational and reporting obligations; potential balance-sheet/revenue effects from accelerated rebate pass-through and compliance costs.
  • Pharmacies, drug manufacturers, and hospitals/healthcare facilities — indirect effects related to confidentiality rules, reimbursement assessments, and infrastructure planning for cell and gene therapies.
  • Division of Insurance, Health Policy Commission, and EOHHS — tasked with oversight, enforcement, and producing the mandated analysis/report.

Potential impacts

  • Short term: reduced patient cost-sharing at point-of-sale (minimum 80% of estimated rebates), administrative/reporting burden on carriers/PBMs, and confidentiality protections limiting public disclosure of detailed rebate data.
  • Medium/long term: the mandated HPC/EOHHS analysis could inform future policy changes on MassHealth reimbursement, infrastructure investments, and equitable access strategies for high-cost cell and gene therapies.

Procedural status and timeline (from provided record)

  • Introduced in Senate: 2025-02-25.
  • Referred to committees (Financial Services; Judiciary cited in actions; record also shows “Referred to Transportation” — appears inconsistent).
  • Hearing scheduled: 2025-06-10 (per record).
  • Annual reporting deadline for carriers under the bill: April 1 (each year).
  • Forecast period specified for the HPC/EOHHS study: 2027–2037.

Notes and uncertainties

  • The bill text and the supplied metadata contain inconsistencies (title, sponsors, and committee referrals). This summary relies on the bill text provided. The full statutory context (e.g., the content of the repealed 2012 sections) and any truncated portions of Section 3 should be reviewed in the official bill version for final legislative analysis.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.